Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Nintedanib is indicated for the treatment of diseases that cause scarring and hardening of the lungs, leading to breathing difficulties. It acts by inhibiting pathological changes ···【more】
Article source：Captain MedicineRelease date：2026-02-03Recommended：148
Elacestrant is the world’s first approved oral selective estrogen receptor degrader (SERD), indicated for the treatment of adult patients with estrogen receptor-positive (ER+), hum···【more】
Article source：Captain MedicineRelease date：2026-02-02Recommended：170
Before starting elacestrant, discuss any questions or concerns with your medical team.What is the recommended dose of Elacestrant?Take one 345 mg tablet once daily. Patients should···【more】
Article source：Captain MedicineRelease date：2026-02-02Recommended：180
Take elacestrant daily and always follow the guidance of your medical team strictly.How Effective is Elacestrant for Treatment?Elacestrant can significantly prolong the progression···【more】
Article source：Captain MedicineRelease date：2026-02-02Recommended：160
Elacestrant is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive malignant tumors.Precautions for Elacestrant UseDyslipidemiaAmo···【more】
Article source：Captain MedicineRelease date：2026-02-02Recommended：160
Anagrelide is indicated to reduce the risk of blood clots in patients with thrombocythemia (an abnormally high platelet count in the blood). Its mechanism of action is to inhibit p···【more】
Article source：Captain MedicineRelease date：2026-01-30Recommended：119
Special caution is required when using anagrelide, as certain drugs may interact with it.What are the drug interactions of Anagrelide?Do not take this medicine with cisapride, dron···【more】
Article source：Captain MedicineRelease date：2026-01-30Recommended：106
Anagrelide may cause a range of side effects during use.What side effects may Anagrelide cause?Inform your doctor promptly if you experience any of the following symptoms that are ···【more】
Article source：Captain MedicineRelease date：2026-01-30Recommended：114
Anagrelide is used to reduce the platelet count in patients with myeloproliferative disorders (platelets are blood cells required for controlling bleeding).What is Anagrelide?Patie···【more】
Article source：Captain MedicineRelease date：2026-01-30Recommended：112
Revumenib (Revuforj) is an oral, first-in-class targeted Menin protein inhibitor indicated for the treatment of relapsed or refractory acute leukemia with specific genetic abnormal···【more】
Article source：Captain MedicineRelease date：2026-01-29Recommended：168
Revumenib (trade name: Revuforj) is an oral, first-in-class targeted Menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with KMT2A gene rearrangem···【more】
Article source：Captain MedicineRelease date：2026-01-29Recommended：150
Revumenib (trade name: Revuforj) is an oral targeted drug of the Menin inhibitor class, indicated for the treatment of relapsed or refractory acute leukemia with KMT2A gene rearran···【more】
Article source：Captain MedicineRelease date：2026-01-29Recommended：178
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4532025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6382024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：952026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4162025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4402025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4252025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4812025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3882025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
